Shivam Chemicals BSE SME IPO review (Avoid)

Review By Dilip Davda on April 20, 2024

•    The company is in Hydrated Lime manufacturing and is a distributor for poultry/animal feed products. 
•    It has posted inconsistency in its top and bottom lines for the reported periods. 
•    From FY23, its top and bottom lines are showing degrowth. 9M-FY24 marked poor performance. 
•    Based on FY24 annualized earnings, the issue appears exorbitantly priced. 
•    There is no harm in skipping this "High Risk/Low Return" bet.

ABOUT COMPANY:
Shivam Chemicals Ltd. (SCL) is a manufacturer of Hydrated Lime (Calcium Hydroxide) & a distributor of various products such as Poultry feed supplement (MBM), Di-Calcium Phosphate (Feed Grade), Magnesium Oxide, Limestone Powder, etc. With rich experience and knowledge, it has built a well-established marketing network across India and it distributes animal feed products for various well renowned manufacture over the years. 

With an average monthly sales volume of 2,650 metric tons, it maintains a consistent presence and contribute to the steady flow of products in the market. Its journey began with a primary focus on animal feed supplement trading till FY 2022-23 and its evolution into manufacturing is happened through the establishment of a 100% owned subsidiary.

SCL's wholly owned subsidiary company Shivam Chemicals and Minerals Private Limited is located at Dahej Gujarat with a manufacturing capacity of 60,000 MT. They are engaged in manufacturing of Hydrated lime (Calcium hydroxide) product. As of December 31, 2023 it had 25 employees on a consolidated basis. It has 12 contracts labours in its subsidiary company i.e. Shivam Chemicals and Minerals Private Limited.

ISSUE DETAILS/CAPITAL HISTORY:
The company is coming out with its maiden IPO of 4587000 equity shares of Rs. 10 each at a fixed price of Rs. 44 per share to mobilize Rs. 20.18 cr. The issue opens for subscription on April 23, 2024, 2024, and will close on April 25, 2024. The minimum application to be made is for 3000 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on BSE SME. The issue constitutes 27.00% of the post-IPO paid-up capital of the company. The company is spending Rs. 2.50 cr. for this IPO process and from the net proceeds of the IPO, it will utilize Rs. 7.05 cr. for working capital, Rs. 5.62 cr. for investment in subsidiary - Shivam Chemicals & Minerals Pvt. Ltd., and Rs. 5.01 cr. for general corporate purposes. 

The issue is solely lead managed by Aryaman Financial Services Ltd., and Cameo Corporate Services Ltd. is the registrar of the issue. Shreni Shares Ltd. is the market maker for the company.  While Aryaman Financial has underwritten the issue to the tune of 94.96%, Shreni Shares has underwritten for 5.04%. 

The company has issued entire equity capital at par value so far and has also issued bonus shares in the ratio of 30 for 1 in September 2023. The average cost of acquisition of shares by the promoters is Rs. NIL, and Rs. 0.32 per share. 

Post-IPO, company's current paid-up equity capital of Rs. 12.40 cr. will stand enhanced to Rs. 16.99 cr. Based on the upper IPO price band, the company is looking for a market cap of Rs. 74.74 cr.  

FINANCIAL PERFORMANCE:
On the financial performance front, for the last three fiscals, the company has posted a total income/net profit of Rs. 95.58 cr. / Rs. 0.87 cr. (FY21), Rs. 177.99 cr. / Rs. 4.44 cr. (FY22), (standalone for FY21 and FY22) and Rs. 156.58 cr. / Rs. 3.57 cr. (FY23), For 9M of FY24, it earned a net profit of Rs. 0.71 cr. on a total income of Rs. 107.11 cr. - on a consolidated basis from FY23 onwards. Thus the company marked inconsistency in its top and bottom lines for the reported periods. 

For the last three fiscals, it has reported an average EPS of Rs. 2.75, and an average RONW of 31.41%. The issue is priced at a P/BV of 3.90 based on its NAV of Rs. 11.29 as of December 31, 2023, and at a P/BV of 2.19 based on its post-IPO NAV of Rs. 20.12 per share.

If we attribute annualized FY24 earnings to its post-IPO fully diluted paid-up capital, then the asking price is at a P/E of 78.57. Based on FY23 earnings, the issue is priced at a P/E of 20.95. Thus the issue appears aggressively priced. 

For the reported periods, the company has posted PAT margins of 0.91% (FY21), 2.49X% (FY22), 2.33% (FY23), 0.66% (9M-FY24), and RoCE margins of 23.84%, 42.35%, 19.88%, 6.19% respectively for the referred periods. 

DIVIDEND POLICY:
The company has not declared any dividends since incorporation. It will adopt a prudent dividend policy based on its financial performance and future prospects. 

COMPARISON WITH LISTED PEERS:
As per the offer document, the company has shown Narmada Agro and Godrej Agrovet as their listed peers. They are trading at a P/E of 54.7 and 33.3 (as of April 19, 2024). However, they are not comparable on an apple-to-apple basis.

MERCHANT BANKER'S TRACK RECORD:
This is the 13th mandate from Aryaman Financial in the last three fiscals (including the ongoing one), out of the last 10 listings, 1 opened at discount, 1 at par, and the rest with premiums ranging from 0.29% to 31.15% on the date of listing.


Conclusion / Investment Strategy

The company is engaged in distributing animal feed/poultry products and is also in the manufacturing of hydrated lime. It is in a highly competitive and fragmented segment. It has marked inconsistency in its top and bottom lines and FY23 onwards, it posted declining trends in its revenue and profits. Based on FY24 annualized earnings, the issue appears exorbitantly priced. There is no harm in skipping this “High Risk/Low Return” bet.

Reviewer recommends Avoid to the issue.

Review By Dilip Davda on April 20, 2024

About Dilip Davda

Dilip Davda, SEBI Registered Research Analyst

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Dilip Davda

SEBI Registered Research Analyst – Mumbai

Registration No.: INH000003127 (Perpetual)

Email: dilip_davda@rediffmail.com


Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

Shivam Chemicals IPO FAQs

The initial public offer (IPO) of Shivam Chemicals Ltd. offers an early investment opportunity in Shivam Chemicals Ltd.. A stock market investor can buy Shivam Chemicals IPO shares by applying in IPO before Shivam Chemicals Ltd. shares get listed at the stock exchanges. An investor could invest in Shivam Chemicals IPO for short term listing gain or a long term.

Read the Shivam Chemicals IPO recommendations by the leading analyst and leading stock brokers.

Shivam Chemicals IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Shivam Chemicals IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts mentioned in the above answer to "How is Shivam Chemicals IPO?"

Our recommendation for Shivam Chemicals IPO is to avoid.

As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to avoid the Shivam Chemicals IPO.

The Shivam Chemicals IPO allotment status will be available on or around April 26, 2024. The allotted shares will be credited in demat account by April 29, 2024. Visit Shivam Chemicals IPO allotment status to check.

The Shivam Chemicals IPO will list on Tuesday, April 30, 2024.

Read more about Shivam Chemicals IPO